Published November 5, 2013 | Version v1
Journal article

Late term tolerance in head neck cancer patients irradiated in the IMRT era

  • 1. Department of Radiation Oncology, University Hospital Zurich, Raemistrasse 100, 8091 Zurich, CH (Switzerland)
  • 2. Clinic for Oral and Maxillofacial, Surgery, University Hospital Zurich, Zurich (Switzerland)
  • 3. Discipline of Oral & Maxillofacial Surgery, Faculty of Dentistry, The University of Hong Kong, Hong Kong, SAR (China)
  • 4. Department of Medical Oncology, University Hospital Zurich, Raemistrasse 100, 8091 Zurich (Switzerland)
  • 5. Department of Otorhinolaryngology, Head and Neck Surgery, University Hospital Zurich, Zurich (Switzerland)
  • 6. Otorhinolaryngology, Klinik Bethanien, Toblerstrasse 51, 8044 Zurich (Switzerland)

Description

The aim was to quantify severe transient and persisting late term effects in our single institution head neck cancer (HNC) cohort treated with curatively intended intensity modulated radiation therapy (IMRT). Hypothesis was if a 2-year follow up (FU) is sufficient to estimate the long term tolerance in HNC irradiated in the IMRT era. Between 01/2002-8/2012, 707/1211 (58%) consecutively treated IMRT patients met the inclusion criteria of a FU time >12 months and loco-regional disease control (LRC). 45% presented with loco-regionally advanced disease; 55% were referred for curative definitive IMRT (66 Gy-72 Gy in 30–35 fractions), 45% underwent postoperative IMRT (60-66 Gy in 30–33 fractions). Systemic concomitant therapy was administered in 85%. Highly consistent treatment procedures were performed with respect to contouring processes, dose constraints, radiation schedules, and the use of systemic therapy. Grade 3/4 late term effects were prospectively assessed and analyzed with respect to subgroups at particular risk for specific late effects. Mean/median FU of the cohort was 41/35 months (15–124). 13% of the patients (92/707) experienced any grade 3/4 late effects (101 events in 92/707 patients), 81% in the first 12 months after radiation. 4% of all developed persisting late grade 3/4 effects (25 events in 25/707 patients). IMRT led to a high late term tolerance in loco-regionally disease free HNC patients. The onset of any G3/4 effects showed a plateau at 2 years. The question of the cervical vessel tolerance in disease free long time survivors is still open and currently under evaluation at our institution

Availability note (English)

Available from http://dx.doi.org/10.1186/1748-717X-8-259; Available from http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4229314

Additional details

Publishing Information

Journal Title
Radiation Oncology (Online)
Journal Volume
8
Journal Page Range
p. 259
ISSN
1748-717X

INIS

Country of Publication
United Kingdom
Country of Input or Organization
International Atomic Energy Agency (IAEA)
INIS RN
47066162
Subject category
S62: RADIOLOGY AND NUCLEAR MEDICINE;
Descriptors DEI
GY RANGE 10-100; HEAD; IRRADIATION; NECK; NEOPLASMS; PATIENTS; RADIATION DOSES; RADIOTHERAPY; TOLERANCE
Descriptors DEC
ABSORBED DOSE RANGE; BODY; DISEASES; DOSES; GY RANGE; MEDICINE; NUCLEAR MEDICINE; RADIATION DOSE RANGES; RADIOLOGY; THERAPY

Optional Information

Copyright
Copyright (c) 2013 Studer et al.
Notes
PMCID: PMC4229314; PUBLISHER-ID: 1748-717X-8-259; PMID: 24192223; OAI: oai:pubmedcentral.nih.gov:4229314; licensee BioMed Central Ltd.